Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy‐Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial

BACKGROUND: For the prevention of chemotherapy‐induced nausea and vomiting (CINV) during the delayed phase (24–120 hours) after moderately emetogenic chemotherapy (MEC), the use of 3‐day dexamethasone (DEX) is often recommended. This study compared the efficacy and safety of two DEX‐sparing regimens...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Vorst, Maurice J.D.L., Toffoli, Elisa C., Beusink, Marlien, van Linde, Myra E., van Voorthuizen, Theo, Brouwer, Saskia, van Zweeden, Annette A., Vrijaldenhoven, Suzan, Berends, Johan C., Berkhof, Johannes, Verheul, Henk M.W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Symptom Management and Supportive Care
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794169/
https://www.ncbi.nlm.nih.gov/pubmed/32735029
http://dx.doi.org/10.1634/theoncologist.2020-0305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794169/
https://www.ncbi.nlm.nih.gov/pubmed/32735029
http://dx.doi.org/10.1634/theoncologist.2020-0305

Ejemplares similares